Clinical Trial

Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients

Study acronym: GBM-FLUX2
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-20; most recent amendment 2025-03-12.
Status change: Recruiting → Active, Not Recruiting 2025-03-12
Trial Details
NCT Number NCT06054529
Lead Sponsor AdventHealth Translational Research Institute
Conditions Glioblastoma Multiforme
Enrollment 2 participants
Start Date 2023-09-11
Primary Completion 2024-01-22 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-13